Suggestions
Justin Hubbard
Product Management at PHC
Dr. Justin Hubbard is a seasoned Product Manager with a unique background in clinical and informatics training, dedicated to revolutionizing healthcare by developing cutting-edge products that enhance patient outcomes on a large scale.
With an impressive educational background including a Doctor of Medicine (MD) from the University of North Carolina along with studies at Harvard Medical School and Harvard University School of Public Health, Dr. Hubbard brings a wealth of knowledge and expertise to his role.
Justin has held key positions in renowned organizations such as PHC Corporation, Nuance Communications, athenahealth, Beth Israel Deaconess Medical Center, and Harvard Medical School, where he has honed his skills in product management, medical information technology, and clinical effectiveness.
Notably, he has spearheaded the product strategy at PHC Corporation and led the product team for Dragon Medical, benefitting over 400,000 physicians across multiple countries.
Dr. Hubbard's multidisciplinary educational background, hands-on experience in diverse healthcare settings, and strategic leadership roles make him a standout professional in the intersection of healthcare, technology, and product development.
Highlights
CMC activities account for nearly 18% of the R&D budget when launching a new drug or biologic.
Last week we announced the launch of a new post-approval variations module for our Cortellis CMC Intelligence™ solution to complement the pre-approval module that was already being used by hundreds of customers. Cortellis CMC Intelligence for post-approval variations enables clients to compare requirements across 64 countries, reducing tracking time and increasing submission rates with organized, timely, and accurate information. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and prioritize essential actions covering both pre- and post-approval documents, Cortellis CMC Intelligence offers comprehensive lifecycle information for drugs and biologics. Serving as a single-platform solution for CMC requirements, it effectively reduces tracking time and unnecessary costs.
This enhancement underscores Clarivate's commitment to simplifying the complexities of CMC regulatory dossier submissions for our clients. By offering transformative insights, Clarivate can accelerate our customers' paths to markets and patients. With the ability to efficiently compare regulations across countries for small molecules and biologics, as well as automate CMC regulatory monitoring through user-configured alerts, clients can navigate the process with confidence and ease.
Cortellis CMC Intelligence curates and tracks official CMC regulations and local practices for more than 135+ countries, territories and organizations for small molecules and 64 countries, territories and regions for biologics, with pre-and post-approval module coverage. Robust data is available for 25+ product and regulatory-related filters based on eCTD structure, including 6K+ source documents and over 2K links to Cortellis Regulatory Intelligence, providing access to expanded detail and in-depth summaries from experts in local regulatory practices, paired with reference source documents, to offer a complete picture. The addition of a new post-approval module now makes a comprehensive CMC solution with complete lifecycle information for drugs and biologics to increase submission rates and avoid costly delays.
#regulatory #pharma #biotech #generics
https://ow.ly/t65930sCeYt
